How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.
EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
EP: 2.Overview of Relapsed/Refractory Multiple Myeloma
EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM
EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma
EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities
EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management
EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Rodriguez discusses how multiple myeloma (MM) is diagnosed and staged. Diagnosis involves blood work such as complete blood count to check hemoglobin, comprehensive metabolic panel to assess renal function and calcium level, serum protein electrophoresis to identify abnormal immunoglobulins (M protein), immunofixation electrophoresis, and serum free light chains to evaluate M protein fragments. These data indicate whether abnormal proteins from myeloma cells are present and their type, quantity, and integrity. Additional blood tests such as lactate dehydrogenase (LDH), β2 microglobulin, and albumin facilitate staging. Urine studies check for free light chains or Bence-Jones proteins. Imaging such as PET-CT identifies lytic bone lesions and extramedullary plasmacytomas. Alternative imaging includes low-dose contrast-enhanced CT or whole-body MRI. Bone marrow biopsy results from the iliac crest or from plasmacytomas characterize disease, and staging uses cytogenetics, albumin, β2 microglobulin, and LDH.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
